According to the World Health Organization, “cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases in 2012.The number of new cases is expected to rise by about 70% over the next 2 decades.
Cancer is the second leading cause of death globally, and was responsible for 8.8 million deaths in 2015. Approximately 70% of deaths from cancer occur in low- and middle-income countries.”
With the development of new therapeutic approaches in Oncology, such as targeted therapy, immuno-oncology combinations, CAR-T and gene therapy, medicine is trying to shift the paradigm from fatal disease to one of chronic or curable disease. The ultimate goal is to improve health around the world. Consequently, this is the area with the highest R&D investment.
Changes and regulatory challenges in this therapeutic area are quite common. Eurotrials is ready to be your partner in oncology research in this era of precision medicine. Whether your aim is to conduct a traditional trial or to implement an alternative study design, our team is ready to guide you through the product life cycle. We are committed to biopharmaceutical, medical device and diagnostic development in the constantly evolving environment of cancer research.
With more than 20 years of experience in the industry, our multidisciplinary team includes medical, operational, strategy and regulatory specialists, as well as market access experts who plan and implement worldwide studies, guiding you and providing you strategic support in every step of the product lifecycle.
Long-term relationships with medical and scientific leaders and research centers in Europe and Latin America contribute to valued expert input for your projects from project design to patient engagement.